Associate Professor Ki-Bum Lee has developed patent-pending technology that may overcome one of the critical barriers to harnessing the full therapeutic potential of stem cells.
One of the major challenges facing researchers interested in regenerating cells and growing new tissue to treat debilitating injuries and diseases such as Parkinson’s disease, heart disease, and spinal cord trauma, is creating an easy, effective, and non-toxic methodology to control differentiation into specific cell lineages. Lee and colleagues at Rutgers and Kyoto University in Japan have invented a platform they call NanoScript, an important breakthrough for researchers in the area of gene expression. Gene expression is the way information encoded in a gene is used to direct the assembly of a protein molecule, which is integral to the process of tissue development through stem cell therapeutics.
Stem cells hold great promise for a wide range of medical therapeutics as they have the ability to grow tissue throughout the body. In many tissues, stem cells have an almost limitless ability to divide and replenish other cells, serving as an internal repair system.
Transcription factor (TF) proteins are master regulators of gene expression. TF proteins play a pivotal role in regulating stem cell differentiation. Although some have tried to make synthetic molecules that perform the functions of natural transcription factors, NanoScript is the first nanomaterial TF protein that can interact with endogenous DNA. ACS Nano, a publication of the American Chemical Society (ACS), has published Lee’s research on NanoScript. The research is supported by a grant from the National Institutes of Health (NIH).
“Our motivation was to develop a highly robust, efficient nanoparticle-based platform that can regulate gene expression and eventually stem cell differentiation,” said Lee, who leads a Rutgers research group primarily focused on developing and integrating nanotechnology with chemical biology to modulate signaling pathways in cancer and stem cells. “Because NanoScript is a functional replica of TF proteins and a tunable gene-regulating platform, it has great potential to do exactly that. The field of stem cell biology now has another platform to regulate differentiation while the field of nanotechnology has demonstrated for the first time that we can regulate gene expression at the transcriptional level.”
NanoScript was constructed by tethering functional peptides and small molecules called synthetic transcription factors, which mimic the individual TF domains, onto gold nanoparticles.
“NanoScript localizes within the nucleus and initiates transcription of a reporter plasmid by up to 30-fold,” said Sahishnu Patel, Rutgers Chemistry graduate student and co-author of the ACS Nano publication. “NanoScript can effectively transcribe targeted genes on endogenous DNA in a nonviral manner.”
The Latest on: Stem Cell Therapeutics
via Google News
The Latest on: Stem Cell Therapeutics
- Verve Therapeutics Presents New Data in Non-Human Primates Validating Gene Editing as a Treatment Approach for Coronary Heart Disease at the ISSCR 2020 Virtual Annual Meetingon June 27, 2020 at 2:45 pm
Verve Therapeutics, a next-generation cardiovascular company, today announced the presentation of new preclinical proof-of-concept data in non-human p ...
- New leader of Minneapolis' Be The Match breaks down stem-cell process, busts mythson June 27, 2020 at 1:39 pm
The international nonprofit organization based in Minneapolis provides lifesaving blood stem cell therapy to people of all ages around the world.
- COVID-19: UAE treats 2,000 virus patients with novel stem cell therapyon June 26, 2020 at 10:27 pm
Abu Dhab: The Abu Dhabi Stem Cell Centre (ADSCC) has now treated more than 2,000 patients suffering from COVID-19, with 1,200 already fully recovered from the effects of the virus. ADSCC announced ...
- C4U and Noile-Immune Biotech partnership on PRIME allogeneic CAR-T cell therapyon June 26, 2020 at 9:21 pm
Immune Biotech and C4U have entered into an agreement on joint research and commercialization of next-generation allogeneic gene-modified immune cell therapy combining C4U's CRISPR/Cas3 genome editing ...
- Stem Cell Market Research Report 2020-2025: Adult, Human Embryonic, & Pluripotent Stem Cells, and Other Typeson June 25, 2020 at 12:15 pm
Growth, Trends and Forecasts (2020-2025)" report has been added to ResearchAndMarkets.com's offering. The global stem cell market is experiencing growth, owing to the increasing number of clinical ...
- Emerging routes to the generation of functional β-cells for diabetes mellitus cell therapyon June 25, 2020 at 6:35 am
This Review highlights the research advances, advantages and challenges in several different strategies for generating functional β-cells for therapeutic use in diabetes mellitus. In addition, ...
- R3 International Offering Stem Cell Therapy Program for Anti Aging in Mexicoon June 23, 2020 at 10:11 pm
R3 Stem Cell International announced a new program offering stem cell therapy for anti aging in Mexico. The program offers several options with stem cell counts up to 200 million and pricing starting ...
- Worldwide Stem Cell Therapy Industry to 2027 - Growth in the Global Healthcare Market Presents Opportunitieson June 18, 2020 at 8:38 am
Global Analysis and Forecasts by Type; Treatment; Application; End User, and Geography" report has been added to ResearchAndMarkets.com's offering.
- Global Stem Cell Therapy Market (2019 to 2027) - by Type, Treatment, Application, End-user, and Geographyon June 18, 2020 at 1:38 am
The "Stem Cell Therapy Market to 2027 - Global Analysis and Forecasts by Type; Treatment; Application; End User, and Geography" report ha ...
- AgeX Therapeutics and Pluristyx Announce Manufacturing, Marketing, and Distribution Agreement to Expand Access to Clinical-Grade Human Pluripotent Stem Cells for Therapeutic ...on June 16, 2020 at 5:00 am
AgeX Therapeutics, Inc. (“AgeX”: NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, and Pluristyx, ...
via Bing News